Stocks Health care COYA
NASDAQ · Health careCoya Therapeutics, Inc. (COYA)
Coya Therapeutics, Inc. brought in $8M of revenue over the twelve months to June 30, 2026, up 1,793.8% from a year earlier. It posted a net loss of $21.7M. At June 30, 2026 it held $43.2M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 11, 2026.
Key facts about Coya Therapeutics, Inc.
- Net worth
- Coya Therapeutics, Inc. has a market value (market cap) of $74.8M at the latest share price, and shareholders' equity of $43.3M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $7.9M (+123.6% year on year), with a net loss of $21.2M. Over the 12 months to June 30, 2026: revenue $8M, net loss $21.7M.
- Cash flow
- In fiscal 2025 operations used $10.7M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 11, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Coya Therapeutics, Inc.'s next report is expected around November 11, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Coya Therapeutics, Inc. does
Coya Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker COYA.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $7.9M | -$21.2M | -$1.27 | n/a |
| 2024 | $3.6M | -$14.9M | -$0.98 | n/a |
| 2023 | $6M | -$8M | -$0.79 | n/a |
| 2022 | $0 | -$12.2M | -$4.73 | n/a |
| 2022 | n/a | -$4.9M | -$1.89 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where COYA ranks in Health care
Latest SEC filings
What Coya Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 5, 2026Other event 8-K
- September 15, 2026Other event 8-K
- August 11, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 49% to $243.7K versus the same quarter last year; diluted EPS -$0.28 versus -$0.36.
- August 11, 2026
- August 7, 2026
- July 27, 2026Passive stake changed SCHEDULE 13G/A
- June 25, 2026
- May 13, 2026
- May 13, 2026Additional proxy material DEFA14A
- May 13, 2026Proxy statement DEF 14A
Insider trades
What the people running Coya Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
Who owns COYA
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| DME Advisors GP, L.L.C.13G, passive with 3 related filers | 9.9% | February 14, 2025 |
| Dr. Reddy's Laboratories, Inc.13G, passive with 2 related filers | 9.7% | March 12, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 54 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| DME Capital Management, LP | 2,335,540 | 0 |
| Vanguard Capital Management LLC | 842,220 | -2,693 |
| Alyeska Investment Group, L.P. | 800,000 | 0 |
| AIGH Capital Management LLC | 631,912 | -343,492 |
| CM Management, LLC | 400,000 | +25,000 |
| Private Management Group Inc | 384,217 | +15,121 |
| Marshall Wace, Llp | 249,793 | +24,001 |
| Geode Capital Management, LLC | 228,243 | -5,159 |
| Renaissance Technologies LLC | 192,986 | +89,022 |
| Prosight Management, LP | 170,000 | -250,360 |
| Dimensional Fund Advisors LP | 155,917 | +59,998 |
| Vanguard Fiduciary Trust Co | 129,551 | -10,335 |
| Jones Financial Companies Lllp | 110,910 | +65,950 |
| BlackRock, Inc. | 102,408 | +19,639 |
| Prelude Capital Management, LLC | 101,330 | 0 |
| JBF Capital, Inc. | 100,006 | 0 |
| Royal Bank of Canada | 93,414 | +80,022 |
| Morgan Stanley | 82,106 | -3,594 |
| State Street Corp | 79,813 | 0 |
| Susquehanna International Group, Llp | 61,006 | +21,690 |
Insiders
Questions about COYA
What does Coya Therapeutics, Inc. do?
Coya Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as COYA. Its shares trade on NASDAQ under the ticker COYA.
What is Coya Therapeutics, Inc.'s net worth?
Coya Therapeutics, Inc. has a market value (market cap) of $74.8M at the latest share price, and shareholders' equity of $43.3M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Coya Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $21.7M on revenue of $8M.
How much revenue does Coya Therapeutics, Inc. make?
Over the twelve months to June 30, 2026 Coya Therapeutics, Inc. reported revenue of $8M. That is 1,793.8% more than a year earlier.
When did Coya Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 11, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the other event from October 5, 2026.
When is Coya Therapeutics, Inc.'s next earnings report?
Coya Therapeutics, Inc.'s next report is expected around November 11, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare COYA with
Follow COYA
Get an email when Coya Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Coya Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.